RE:RE:RE:RE:FYI - a call to arms from TH's RBC analyst
I have faith in TH, Fred. To me, after years in biotech investment, I realized that the only thing you can count on in management is Ethics. I believe this management is ethical: they meant what they said.
Even both Trogarzo and Egrifta in their current forms and breadth could be improved to be profitable, yet I don't think they could get TH that far, well, in terms of Share Price. So, to be rewarded after all those years, the only hope is NASH for Egrifta. Everything would hinge on it and with it, the green light for Phase 3 NASH for HIV patients. Based on current design as proposed, I think there is more than 60% chance of a successful outcome.
Good luck, Fred.